Earth Science Tech Inc. (ETST) Offers Innovative,

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
729
Earth Science Tech Inc. (ETST) Offers Innovative, Well-Branded CBD Products

- Earth Science Tech operates through diverse subsidiaries in the CBD space
- The company offers a wide range of CBD products, as well as its MSN-2 medical device
- ETST has varied distribution agreements in place to strengthen its foothold in the CBD marketplace

Earth Science Tech Inc. (OTCQB: ETST) is a biotechnology company operating in varied and vibrant market sectors, including hemp cannabidiol (CBD), nutraceuticals, pharmaceuticals and medical-device research and development. Headquartered in Doral, Florida, the company functions by way of diverse, wholly owned subsidiaries centered on developing its role as a global leader in the CBD space. These subsidiaries are also expanding Earth Science Tech’s work in the pharmaceutical and medical-device sectors.

Earth Science Pharmaceutical Inc. is one of the company’s subsidiaries. Its emphasis is on becoming a worldwide leader in the development of low-cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases) (http://nnw.fm/6OsdL). The first medical device offered by Earth Science Pharmaceutical is the MSN-2 Chlamydia Home Kit Screening, designed to detect STIs.

The company’s technology depends on the use of a modified panty liner (MSN-2) worn for four hours to collect a sample of human cells. The liner is then sent to a designated lab, where the cells are subsequently analyzed employing a proven and established process. Modified panty liners have less- strict transport criteria than urine or vaginal swabs. The company is advancing clinical trials of MSN-2 via a collaborative agreement with Laboratories BNK Canada (http://nnw.fm/t05pT).

Another subsidiary of Earth Science Tech is Cannabis Therapeutics Inc. Cannabis Therapeutics is committed to become a global leader in cannabinoid research and development (R&D) for an extensive line of cannabinoid-based pharmaceuticals, nutraceuticals and other products and solutions. Its mission is to help change the health care landscape by introducing proprietary products made for the global pharmaceutical- and retail-consumer markets.

Cannabis Therapeutics has a provisional application patent for CBD and is invested in R&D to explore and harness the medicinal power of cannabidiol. The company is working to develop CBD-based drugs and nutraceutical products and is also working to integrate CBD molecules with existing generic drug molecules. Cannabis Therapeutics is concentrating on developing pioneering products that provide treatment options for patients and physicians.

Furthermore, Earth Science Tech has its Canna Inno Laboratories Inc. subsidiary. Earth Science Tech established this subsidiary in 2017 to carve out a position in the Canadian province of Québec, giving ETST inside access to the thriving Canadian CBD market. Canna Inno Laboratories provides ETST with access to government grants offered to innovators in the pharmaceutical industry; Canna Inno’s first grant has received approval (http://nnw.fm/f01O6).

Overall, Earth Science Tech offers its unique product lineup in varied forms including liquids, tablets, capsules, soft gels, sprays, chewables, creams, whole herbs and powders. The company’s product family includes CBD oil for pets, flavored and infused CBD oils and a line of organic chocolate CBD products. The company’s CBD oil is 100 percent natural and organic and is manufactured using a supercritical CO2 liquid extraction process.

Earth Science Tech also has key distribution agreements in place to further the market reach of its products. This year, the company signed agreements to distribute CBD products via pharmacies, chiropractors, dispensaries, athletic clubs and clinics (http://nnw.fm/Q0zqC). ETST is advancing product placement in large chains, health-food stores and other establishments, and the agreements are for the distribution of a high-grade, full-spectrum cannabinoid line. Agreements are in place with CannaBiz and Desert Sun Distribution.

Moreover, Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to work on projects that scientifically support and advance the health care benefits of the company’s high-grade, hemp-CBD oil.

Earth Science Tech continues to focus on the new frontier involving the innovative integration of CBD with generic drug molecules. With a management team that has decades of invaluable experience in the nutraceutical, dietary supplement, and life sciences sectors, ETST offers investors an attractive opportunity in the emerging CBD space. Earth Science Tech remains dedicated to growing its product portfolio and customer base.

For more information, visit the company’s website at www.EarthScienceTech.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Earth Science Tech, Inc. (ETST) Stock Research Links

ETST Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading